Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by polygraph46on Apr 06, 2020 5:27pm
93 Views
Post# 30884576

Common Shareholders Destiny

Common Shareholders DestinyWhyme16.....with the way this play is going, if I were you I wouldn't hold my breath waiting for Management reply.  There has to be reasons.
(a) from a personal standpoint, I don't think shareholders would be happy with their  answers.  (b) As retail holders (aka outsiders) we are not on the pulse in regards to what is really going on inside Kaly...... which of course is not surprising with the Venture Ex.
(c) again, why management silence?  Well, in my thinking.......no response is very often, a response!  Could be red flags. 
Like, why are we well into the third year of intentions to start Phase 3 GVHD? I would surely like to know because, with the repeated delays of startup, no identified partner/suitor, could it be that the great promising research may not be what it's craced up to be?
Be nice to have some answers........pg46
Bullboard Posts